The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Your search for esrd returned 17 results
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
This study raises important questions about the choice between lactated Ringer and saline.
Study findings highlight an “unmet need” for newer therapies.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.